Related Experiment Videos
[Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits]
Abstract:
Norfloxacin (NFLX), a new quinolone antibiotic agent, was evaluated for its efficacy in experimental osteomyelitis in rabbits. Osteomyelitis was induced in male rabbits by the inoculation of 10(7) CFU/ml (0.1 ml) of Staphylococcus aureus (MIC for NFLX: 0.78 micrograms/ml) with 0.4 ml of 3% sodium tetradecyl sulphate into the medullary cavity of the proximal tibia. The rabbits were divided into 3 different groups of 4 animals each. The animals in 2 groups were orally administered with NFLX; 100 mg/kg once-daily (group 2) and 50 mg/kg twice-daily (group 3) for 7 days from the 6th hour after inoculation. Group 1 was established as a control without administration of NFLX. All animals were sacrificed on the 7th day after inoculation. Acute osteomyelitic changes were found microscopically in all animals in group 1. In each of the 2 therapeutic groups, incidence of microscopic changes was 50% associated with remission of S-sialic acid value. Thus, NFLX may be considered a useful antimicrobial agent for the treatment of suppurative osteomyelitis.
Insights
Norfloxacin (NFLX) effectively treated experimental Staphylococcus aureus osteomyelitis in rabbits. This quinolone antibiotic showed a 50% incidence of microscopic healing, suggesting its potential for treating bone infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Veterinary Medicine
Context:
- Osteomyelitis is a serious bone infection often caused by Staphylococcus aureus.
- Developing effective antimicrobial treatments for osteomyelitis remains a clinical challenge.
- Experimental models are crucial for evaluating new antibiotic therapies.
Purpose:
- To assess the efficacy of Norfloxacin (NFLX) in a rabbit model of experimental osteomyelitis.
- To determine optimal dosing regimens for Norfloxacin in treating bone infections.
- To evaluate the impact of Norfloxacin on histological osteomyelitic changes and S-sialic acid levels.
Summary:
- Experimental osteomyelitis was induced in rabbits using Staphylococcus aureus.
- Norfloxacin was administered orally at two different dosages (100 mg/kg once daily and 50 mg/kg twice daily) for seven days.
- Microscopic examination revealed a 50% reduction in osteomyelitic changes in Norfloxacin-treated groups, correlating with S-sialic acid remission.
Impact:
- Norfloxacin demonstrates potential as an effective antimicrobial agent for treating suppurative osteomyelitis.
- The study provides evidence supporting the use of Norfloxacin in managing bone infections.
- Findings contribute to the understanding of quinolone efficacy in infectious disease treatment.